Personalized medicine is a disruptive innovation that will change the structure of the pharmaceutical industry in the future!
Speaker Pharma Marketing Consultant Mr. Ryoichi Inoue Target Audience: Individuals interested in personalized medicine and orphan drugs Venue: Kawasaki City Industrial Promotion Hall, Room 1 [Kanagawa, Kawasaki] A 5-6 minute walk from JR and Keikyu "Kawasaki Station" Date and Time: April 26, 2011 (Tuesday) 13:00-16:00 Capacity: 30 people *Registration will close once full. Please apply early.
Inquire About This Product
basic information
**Course Objectives and Aims** The pharmaceutical industry worldwide, including Japan, is entering a period of significant structural change. Large low-molecular-weight drugs, such as those for lifestyle-related diseases that have led the growth of the pharmaceutical market in the past, are now facing patent expirations one after another, being replaced by generics, resulting in a substantial decline in sales. However, due to changes in disease structures and the emergence of new unmet medical needs, antibody drugs and molecular targeted therapies, particularly for cancer and autoimmune diseases, are experiencing rapid growth. These drugs represent "personalized medicine," where treatment methods differ based on individual genetic information, and diagnostic drugs are paired with pharmaceuticals. I would like to present that this personalized medicine is a disruptive innovation that will change the structure of the pharmaceutical industry in the future. Furthermore, an important growth area is "rare and intractable diseases." The development of drugs for these diseases is encouraged by various countries' "orphan drug systems," which have traditionally been viewed as "products for a small number of patients that do not sell well, treated by specialized companies." Recently, however, major Western pharmaceutical companies such as Novartis, GSK, Pfizer, and Sanofi-Aventis have begun to energetically enter this field. In this context, do Japan's top four companies, as well as mid-sized firms, have viable survival strategies? We will discuss whether these survival strategies are feasible.
Price information
46200
Price range
P2
Delivery Time
P2
Applications/Examples of results
1. Overview of the Global Pharmaceutical Industry 2. Status of New Drug Approvals by the FDA in 2010 3. Global Pharmaceutical Market Forecast for 2015 4. The End of Medications for Lifestyle-Related Diseases 5. Rapid Growth of Antibody and Molecular Targeted Drugs 6. Personalized Medicine and Its Examples 7. Three Major Factors Enabling Personalized Medicine 8. Personalized Medicine as Disruptive Innovation 9. System and Approval Status of Orphan Drugs 10. Sales of Orphan Drugs 11. Epidemiology of Rare Diseases 12. Entry of Western Mega-Pharma into the Rare Disease Sector 13. Business Models of Orphan Drugs 14. Classification of Management Strategies of Global Pharmaceutical Companies 15. Survival Strategies of Japan's Top 4 and Mid-Tier Pharmaceutical Companies 16. Survival Strategies of Japan's Mid-Sized Pharmaceutical Companies 17. Q&A
Company information
Our company has developed its business from "seminar planning" to various forms such as "lecturer dispatch," "publishing planning," "technical consultant dispatch," "trend research," "business matching," and "business development consulting," in order to support clients in a wide range of fields including chemistry, electronics, automotive, energy, medical devices, food, and building materials. By doing so, we have advanced our company and opened up new markets. AndTech promises to continue listening to our clients' voices, entering the business areas and markets they desire, and to remain a company that is loved by our clients, as we share their challenges, think together, and forge new paths.
